These findings suggest that AAV‐shAsprosin can compensate for the limitations of fenofibrate in the treatment of MASH, and that inhibition of hepatic asprosin may be an effective option for the treatment of MASLD/MASH. This evidence concerns the gene FBN1 and metabolic dysfunction-associated steatotic liver disease.